As GLP-1 receptor agonists are currently widely used in clinical practice to treat obesity/type 2 diabetes, it is necessary to determine the effects of GLP-1 on the reproductive system in humans. This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.